RBM12B

Summary

RBM12B (RNA binding motif protein 12B, HGNC:32310) is a protein-coding gene on chromosome 8q22.1, encoding RNA-binding protein 12B (Q8IXT5).

Enables RNA binding activity. Predicted to be involved in regulation of RNA splicing. Predicted to be part of ribonucleoprotein complex. Predicted to be active in nucleoplasm.

Source: NCBI Gene 389677 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 165 total
• Druggable target: yes
• MANE Select transcript: NM_001377960

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32310
Approved symbol	RBM12B
Name	RNA binding motif protein 12B
Location	8q22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000183808
Ensembl biotype	protein_coding
Entrez	389677

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 25 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000399300, ENST00000517700, ENST00000518597, ENST00000519109, ENST00000520560, ENST00000520961, ENST00000891584, ENST00000891585, ENST00000891586, ENST00000891587, ENST00000891588, ENST00000891589, ENST00000891590, ENST00000891591, ENST00000891592, ENST00000891593, ENST00000932408, ENST00000932409, ENST00000932410, ENST00000932411, ENST00000932412, ENST00000932413, ENST00000932414, ENST00000932415, ENST00000963705, ENST00000963706

RefSeq mRNA: 6 — MANE Select: NM_001377960 NM_001377960, NM_001377961, NM_001377962, NM_001377963, NM_001377964, NM_203390

CCDS: CCDS43755

Canonical transcript exons

ENST00000520560 — 4 exons

Exon	Start	End
ENSE00001537396	93728155	93736438
ENSE00001537397	93737307	93737355
ENSE00002096289	93740629	93740696
ENSE00002111316	93740881	93741009

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 91.94.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.0040 / max 618.1161, expressed in 1806 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
93968	9.9478	1709
93969	8.5200	1755
93965	2.1936	1093
93970	1.0358	609
93967	0.8393	495
93966	0.4674	251

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	91.94	gold quality
adrenal tissue	UBERON:0018303	90.82	gold quality
caput epididymis	UBERON:0004358	88.90	gold quality
corpus epididymis	UBERON:0004359	88.76	gold quality
buccal mucosa cell	CL:0002336	87.78	gold quality
tendon	UBERON:0000043	86.93	gold quality
ganglionic eminence	UBERON:0004023	86.48	gold quality
cauda epididymis	UBERON:0004360	86.46	gold quality
ventricular zone	UBERON:0003053	85.98	gold quality
colonic epithelium	UBERON:0000397	84.98	gold quality
cortical plate	UBERON:0005343	84.94	gold quality
endothelial cell	CL:0000115	84.80	gold quality
superficial temporal artery	UBERON:0001614	84.69	gold quality
ovary	UBERON:0000992	84.63	gold quality
left ovary	UBERON:0002119	84.63	gold quality
sural nerve	UBERON:0015488	84.08	gold quality
lymph node	UBERON:0000029	83.90	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.44	gold quality
endometrium	UBERON:0001295	83.21	gold quality
right ovary	UBERON:0002118	82.85	gold quality
corpus callosum	UBERON:0002336	82.31	gold quality
rectum	UBERON:0001052	81.93	gold quality
body of uterus	UBERON:0009853	81.92	gold quality
islet of Langerhans	UBERON:0000006	81.77	gold quality
vermiform appendix	UBERON:0001154	81.74	gold quality
embryo	UBERON:0000922	81.56	gold quality
stromal cell of endometrium	CL:0002255	81.44	gold quality
endocervix	UBERON:0000458	81.05	gold quality
mammary duct	UBERON:0001765	80.58	gold quality
leukocyte	CL:0000738	80.54	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

133 targeting RBM12B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-6759-5P	99.99	66.54	785
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	rbm12ba	ENSDARG00000055889
danio_rerio	rbm12bb	ENSDARG00000079717
mus_musculus	Rbm12b1	ENSMUSG00000046667
mus_musculus	Rbm12b2	ENSMUSG00000052137
rattus_norvegicus	Rbm12b	ENSRNOG00000016330
rattus_norvegicus	LOC120102832	ENSRNOG00000055292
drosophila_melanogaster	fus	FBGN0023441
drosophila_melanogaster	glo	FBGN0259139
caenorhabditis_elegans		WBGENE00006367
caenorhabditis_elegans	rbm-12	WBGENE00013703
caenorhabditis_elegans		WBGENE00022253

Paralogs (8): HNRNPH3 (ENSG00000096746), ESRP2 (ENSG00000103067), ESRP1 (ENSG00000104413), HNRNPH2 (ENSG00000126945), GRSF1 (ENSG00000132463), HNRNPH1 (ENSG00000169045), HNRNPF (ENSG00000169813), RBM12 (ENSG00000244462)

Protein

Protein identifiers

RNA-binding protein 12B — Q8IXT5 (reviewed: Q8IXT5)

Alternative names: RNA-binding motif protein 12B

All UniProt accessions (5): B9ZVT1, E5RHG1, E5RJ83, E5RJV8, Q8IXT5

RefSeq proteins (6): NP_001364889, NP_001364890, NP_001364891, NP_001364892, NP_001364893, NP_976324 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034588	RBM12B_RRM2	Domain
IPR034858	RBM12B_RRM3	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR047188	RRM4_RBM12B	Domain
IPR050666	ESRP	Family

Pfam: PF00076

UniProt features (40 total): modified residue 18, cross-link 6, domain 4, compositionally biased region 4, region of interest 4, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXT5-F1	56.09	0.11

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (24): 98, 101, 112, 250, 254, 276, 278, 280, 292, 294, 319, 377, 575, 591, 638, 640, 710, 718, 114, 151 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 77 (showing top): PATIL_LIVER_CANCER, GOBP_RNA_SPLICING, NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON, chr8q22, GTGACTT_MIR224, GOBP_REGULATION_OF_RNA_SPLICING, TGGAAA_NFAT_Q4_01, GOCC_RIBONUCLEOPROTEIN_COMPLEX, MMEF2_Q6, STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7, STAT6_01, DURAND_STROMA_NS_UP, ZWANG_EGF_INTERVAL_UP, FOXN3_TARGET_GENES

GO Biological Process (1): regulation of RNA splicing (GO:0043484)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (2): nucleoplasm (GO:0005654), ribonucleoprotein complex (GO:1990904)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
RNA splicing	1
regulation of gene expression	1
regulation of primary metabolic process	1
nucleic acid binding	1
nuclear lumen	1
cellular anatomical structure	1
protein-containing complex	1

Protein interactions and networks

STRING

1158 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RBM12B	TSKS	Q9UJT2	590
RBM12B	TRABD	Q9H4I3	504
RBM12B	TBC1D22A	Q8WUA7	491
RBM12B	YLPM1	P49750	473
RBM12B	THAP2	Q9H0W7	446
RBM12B	SLCO6A1	Q86UG4	418
RBM12B	C6orf120	Q7Z4R8	373
RBM12B	TMEM68	Q96MH6	371
RBM12B	ZNF253	O75346	366
RBM12B	MTCL1	Q9Y4B5	358
RBM12B	ASB12	Q8WXK4	352
RBM12B	C11orf96	Q7Z7L8	348
RBM12B	NHLRC3	Q5JS37	340
RBM12B	COPS7B	Q9H9Q2	340
RBM12B	DAD1	P46966	329

IntAct

44 interactions, top by confidence:

A	B	Type	Score
HNRNPH2	PLOD2	psi-mi:“MI:0914”(association)	0.530
RBM12B	CACNA1A	psi-mi:“MI:0915”(physical association)	0.510
RBMX	RBM12B	psi-mi:“MI:0915”(physical association)	0.400
Racgap1	DDX3X	psi-mi:“MI:0914”(association)	0.350
Taf15	BTBD10	psi-mi:“MI:0914”(association)	0.350
Ctnnbl1	LCMT2	psi-mi:“MI:0914”(association)	0.350
MATR3	BCLAF3	psi-mi:“MI:0914”(association)	0.350
HNRNPA1	MATR3	psi-mi:“MI:0914”(association)	0.350
Slain1	OARD1	psi-mi:“MI:0914”(association)	0.350
Hnrnpa3	MATR3	psi-mi:“MI:0914”(association)	0.350
Fus	DDX3X	psi-mi:“MI:0914”(association)	0.350
PPP1CC	CLIC1	psi-mi:“MI:0914”(association)	0.350
PPP1CB	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
Srsf1	SRRM1	psi-mi:“MI:0914”(association)	0.350
RRP1B	ZNF785	psi-mi:“MI:0914”(association)	0.350
AURKB	HSP90AA1	psi-mi:“MI:0914”(association)	0.350
rep	VWA8	psi-mi:“MI:0914”(association)	0.350
MAP1LC3A		psi-mi:“MI:0914”(association)	0.350
CASP8	CCN1	psi-mi:“MI:0914”(association)	0.350
RB1	ZNF593	psi-mi:“MI:0914”(association)	0.350
SHANK3	IGKV3D-15	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
RBM12B	RNF40	psi-mi:“MI:0914”(association)	0.350
POMGNT2	FAM83G	psi-mi:“MI:0914”(association)	0.350
SF3B1	RBM10	psi-mi:“MI:0914”(association)	0.350
ATF3	C11orf98	psi-mi:“MI:0914”(association)	0.350
GATA2	C11orf98	psi-mi:“MI:0914”(association)	0.350
CTNNA1	EFCAB5	psi-mi:“MI:0914”(association)	0.350

BioGRID (101): RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Proximity Label-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS), RBM12B (Affinity Capture-MS)

ESM2 similar proteins: A0A0J9YWL9, A0A0J9YY54, A0A1D9BZF0, A0A494C071, A6NDE4, A6NEQ0, A6QL64, A8MQ14, B3KS81, E9Q6E9, O77733, P05995, P0C7P1, P0C8Z4, P0DJD3, P0DJD4, P0DKJ7, P0DKJ8, P0DKL2, P0DPF3, P11088, P18751, P18753, P20930, P97347, Q15415, Q2VIS4, Q3BBV2, Q42626, Q5D862, Q5HY64, Q5JPF3, Q5U7M9, Q6JHY2, Q6P3W6, Q6XPR3, Q86T75, Q86VE3, Q86YZ3, Q8IXT5

Diamond homologs: A1L1G1, A8WPC5, B2RYD2, B2RYJ8, O35737, P31942, P31943, P52597, P55795, P70333, Q12849, Q22708, Q3SZF3, Q3US41, Q5E9J1, Q5RD26, Q5RFT7, Q60HC3, Q6AY09, Q6DEZ7, Q6NXG1, Q794E4, Q7ZY29, Q8C5Q4, Q8IXT5, Q8K0G8, Q8R3C6, Q8VHV7, Q9Y4C8, Q9Z2X1, Q15020, Q5REG1, Q5ZLR4, Q5RBM8, Q66JV4, Q80YR9, Q8R4X3, Q8SQ27, Q9NTZ6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 66 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA 3’-end processing	5	25.2×	8e-05
mRNA Polyadenylation	10	22.5×	4e-09
Transport of Mature mRNA derived from an Intron-Containing Transcript	5	19.5×	2e-04
Processing of Capped Intron-Containing Pre-mRNA	9	19.0×	7e-08
mRNA Splicing	6	16.9×	8e-05
mRNA Splicing - Major Pathway	11	15.4×	1e-08
Dengue Virus-Host Interactions	10	11.7×	6e-07
Metabolism of RNA	6	6.4×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of alternative mRNA splicing, via spliceosome	5	23.5×	2e-04
mRNA splicing, via spliceosome	11	19.4×	4e-09
RNA splicing	9	15.3×	2e-06
mRNA processing	8	12.1×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

165 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	150
Likely benign	11
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1022 predictions. Top by Δscore:

Variant	Effect	Δscore
8:93737351:CTTAA:C	acceptor_gain	1.0000
8:93737352:TTAA:T	acceptor_gain	1.0000
8:93737356:C:CC	acceptor_gain	1.0000
8:93728203:A:AG	acceptor_gain	0.9900
8:93728204:G:GG	acceptor_gain	0.9900
8:93728204:GGT:G	acceptor_gain	0.9900
8:93737353:TAA:T	acceptor_gain	0.9900
8:93740861:A:AC	donor_gain	0.9900
8:93740862:C:CC	donor_gain	0.9900
8:93740878:CACCA:C	donor_gain	0.9900
8:93740880:CCA:C	donor_gain	0.9900
8:93733728:TGCC:T	donor_gain	0.9800
8:93738823:CA:C	donor_gain	0.9700
8:93740880:C:CT	donor_gain	0.9700
8:93736369:C:T	acceptor_gain	0.9600
8:93740900:A:T	donor_gain	0.9600
8:93728201:A:G	acceptor_gain	0.9500
8:93733727:TTGC:T	donor_gain	0.9500
8:93736435:TGACC:T	acceptor_loss	0.9500
8:93736436:GACC:G	acceptor_loss	0.9500
8:93736439:C:CA	acceptor_loss	0.9500
8:93736440:T:G	acceptor_loss	0.9500
8:93737305:ACC:A	acceptor_loss	0.9500
8:93737355:AC:A	acceptor_loss	0.9500
8:93737356:C:G	acceptor_loss	0.9500
8:93737357:T:A	acceptor_loss	0.9500
8:93740624:TATAC:T	donor_loss	0.9500
8:93740625:ATAC:A	donor_loss	0.9500
8:93740626:TA:T	donor_loss	0.9500
8:93740627:ACC:A	donor_loss	0.9500

AlphaMissense

785 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:93736245:C:G	A56P	0.997
8:93736244:G:T	A56D	0.996
8:93736270:A:C	F47L	0.996
8:93736270:A:T	F47L	0.996
8:93736272:A:G	F47L	0.996
8:93736284:C:G	A43P	0.996
8:93736254:C:G	A53P	0.995
8:93736271:A:G	F47S	0.995
8:93736279:A:C	F44L	0.995
8:93736279:A:T	F44L	0.995
8:93736281:A:G	F44L	0.995
8:93736394:C:G	R6P	0.995
8:93736189:A:C	S74R	0.994
8:93736189:A:T	S74R	0.994
8:93736191:T:G	S74R	0.994
8:93736199:A:G	L71P	0.994
8:93736382:A:G	L10P	0.994
8:93736253:G:T	A53E	0.993
8:93736328:A:T	I28N	0.991
8:93736343:A:G	F23S	0.991
8:93736352:C:G	R20P	0.991
8:93736400:A:T	V4D	0.991
8:93736249:T:A	R54S	0.990
8:93736249:T:G	R54S	0.990
8:93736391:A:G	L7S	0.990
8:93736247:C:G	R55P	0.989
8:93736328:A:C	I28S	0.989
8:93736271:A:C	F47C	0.988
8:93736277:A:T	I45N	0.988
8:93736283:G:T	A43D	0.988

dbSNP variants (sampled 300 via entrez): RS1000012792 (8:93731513 A>C), RS1000019856 (8:93739968 A>G), RS1000154700 (8:93733051 GAA>G,GA,GAAA), RS1000218085 (8:93734570 G>A,C), RS1000436730 (8:93741060 A>C,G), RS1001468709 (8:93738763 G>GT), RS1001712613 (8:93742414 C>G,T), RS1001845687 (8:93736422 A>G), RS1001888276 (8:93736084 A>C), RS1002118153 (8:93729516 T>C), RS1002164814 (8:93742072 T>C), RS1002256822 (8:93732875 G>GT), RS1002509829 (8:93739629 C>G,T), RS1002656135 (8:93731099 G>A), RS1002786082 (8:93732633 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): myoepithelial tumor (MONDO:0002380)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196110 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation	4
trichostatin A	affects cotreatment, decreases expression	2
sodium arsenite	decreases expression, affects cotreatment, increases abundance	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Rotenone	decreases expression	2
Cadmium Chloride	increases expression, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases methylation	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
coumarin	affects phosphorylation	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
fatostatin	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6096343	Binding	Binding affinity to RBM12B at C204 residue in human MDA-MB-231 cells at 1 uM incubated for 3 hrs in presence of IAA by proteome-wide scale isoTOP ABPP method	Covalent Inhibitors of KEAP1 with Exquisite Selectivity. — J Med Chem

Clinical trials (associated diseases)

5 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis